로딩 중…
StockDiggingStockDigging

Bausch Health Companies Inc.

BHC· NYSE
CACA
$8.21-7.86%
2026-10-30

Financials

Valuation Metrics

Bausch Health Companies Inc.'s Market Cap is $3.07B. At end of 2025 it was $2.58B. Ranked #1635 of 3,116 in US market (top 52%), #1061 of 1,644 on NYSE (top 65%), #95 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.

Investment Metrics(as of 2026-10-30)

MetricValue
Size
Market Cap$3.07B
Revenue$10.85B
Net Income$-1.10B
Total Assets$24.79B
Net Assets$-1.77B
Employees20,300
Value
P/S0.28x
EV/EBITDA10.76x
FCF Yield45.41%
Profitability
ROA-4.43%
Op. Margin25.44%
Revenue Growth10.09%
Earnings Growth-1220.41%
Financial Health
Total Debt$20.78B
FCF$1.39B
Cash$1.82B
Current Ratio1.44x
Net Debt/EBITDA9.26x
Performance
1Y Return24.21%
1M Return40.82%
From 52W High-9.18%
1Y MDD-43.92%
Trading
Volume8,044,499 shares
Trading Value$68M
Per Share
EPS$-2.94
BPS$-4.74

Company Info

CEO Thomas J. Appio
Employees 20,300
HQ Laval, CA

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.